Harbin Gloria Pharmaceuticals Co., Ltd (002437.SZ)
CNY 2.69
(-0.74%)
CNY 2.69
(-0.74%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.42 Billion CNY | -39.92% |
| 2022 | 2.37 Billion CNY | -12.72% |
| 2021 | 2.71 Billion CNY | 5.14% |
| 2020 | 2.58 Billion CNY | -46.39% |
| 2019 | 4.81 Billion CNY | -5.2% |
| 2018 | 5.08 Billion CNY | 5.65% |
| 2017 | 4.81 Billion CNY | 4.15% |
| 2016 | 4.61 Billion CNY | -4.66% |
| 2015 | 4.84 Billion CNY | 166.22% |
| 2014 | 1.82 Billion CNY | 291.77% |
| 2013 | 464.6 Million CNY | 127.98% |
| 2012 | 203.78 Million CNY | 77.35% |
| 2011 | 114.9 Million CNY | 55.85% |
| 2010 | 73.72 Million CNY | -52.42% |
| 2009 | 154.94 Million CNY | 81.94% |
| 2008 | 85.16 Million CNY | 10.39% |
| 2007 | 77.14 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 1.21 Billion CNY | -14.39% |
| 2024 Q2 | 882.09 Million CNY | -27.66% |
| 2024 Q3 | 912.54 Million CNY | 3.45% |
| 2023 Q3 | 1.7 Billion CNY | -10.06% |
| 2023 Q4 | 1.42 Billion CNY | -16.28% |
| 2023 FY | 1.42 Billion CNY | -39.92% |
| 2023 Q1 | 2.23 Billion CNY | -5.72% |
| 2023 Q2 | 1.89 Billion CNY | -15.37% |
| 2022 Q3 | 2.49 Billion CNY | -2.12% |
| 2022 FY | 2.37 Billion CNY | -12.72% |
| 2022 Q4 | 2.37 Billion CNY | -5.12% |
| 2022 Q2 | 2.55 Billion CNY | 0.05% |
| 2022 Q1 | 2.55 Billion CNY | -6.07% |
| 2021 FY | 2.71 Billion CNY | 5.14% |
| 2021 Q4 | 2.71 Billion CNY | -7.95% |
| 2021 Q1 | 2.91 Billion CNY | 12.77% |
| 2021 Q2 | 2.86 Billion CNY | -1.5% |
| 2021 Q3 | 2.95 Billion CNY | 2.84% |
| 2020 Q2 | 3.27 Billion CNY | -7.28% |
| 2020 Q4 | 2.58 Billion CNY | -11.96% |
| 2020 FY | 2.58 Billion CNY | -46.39% |
| 2020 Q1 | 3.52 Billion CNY | -26.79% |
| 2020 Q3 | 2.93 Billion CNY | -10.29% |
| 2019 Q1 | 4.89 Billion CNY | -3.79% |
| 2019 FY | 4.81 Billion CNY | -5.2% |
| 2019 Q4 | 4.81 Billion CNY | -2.07% |
| 2019 Q3 | 4.92 Billion CNY | -0.18% |
| 2019 Q2 | 4.92 Billion CNY | 0.8% |
| 2018 Q4 | 5.08 Billion CNY | 5.3% |
| 2018 Q3 | 4.82 Billion CNY | -2.73% |
| 2018 FY | 5.08 Billion CNY | 5.65% |
| 2018 Q1 | 4.99 Billion CNY | 3.81% |
| 2018 Q2 | 4.96 Billion CNY | -0.63% |
| 2017 Q4 | 4.81 Billion CNY | -1.44% |
| 2017 FY | 4.81 Billion CNY | 4.15% |
| 2017 Q1 | 4.51 Billion CNY | -2.19% |
| 2017 Q2 | 4.68 Billion CNY | 3.71% |
| 2017 Q3 | 4.88 Billion CNY | 4.17% |
| 2016 Q2 | 4.59 Billion CNY | 1.9% |
| 2016 Q1 | 4.51 Billion CNY | -6.92% |
| 2016 Q4 | 4.61 Billion CNY | 1.64% |
| 2016 Q3 | 4.54 Billion CNY | -1.11% |
| 2016 FY | 4.61 Billion CNY | -4.66% |
| 2015 Q1 | 3.67 Billion CNY | 101.93% |
| 2015 FY | 4.84 Billion CNY | 166.22% |
| 2015 Q3 | 4.33 Billion CNY | 12.19% |
| 2015 Q4 | 4.84 Billion CNY | 11.69% |
| 2015 Q2 | 3.86 Billion CNY | 5.21% |
| 2014 Q4 | 1.82 Billion CNY | 20.51% |
| 2014 Q3 | 1.51 Billion CNY | -9.5% |
| 2014 FY | 1.82 Billion CNY | 291.77% |
| 2014 Q1 | 1.09 Billion CNY | 136.5% |
| 2014 Q2 | 1.66 Billion CNY | 51.89% |
| 2013 Q2 | 433.59 Million CNY | 57.42% |
| 2013 Q4 | 464.6 Million CNY | 1.53% |
| 2013 FY | 464.6 Million CNY | 127.98% |
| 2013 Q1 | 275.44 Million CNY | 35.16% |
| 2013 Q3 | 457.6 Million CNY | 5.54% |
| 2012 Q4 | 203.78 Million CNY | -20.25% |
| 2012 FY | 203.78 Million CNY | 77.35% |
| 2012 Q3 | 255.54 Million CNY | 64.31% |
| 2012 Q2 | 155.52 Million CNY | 10.2% |
| 2012 Q1 | 141.13 Million CNY | 22.83% |
| 2011 Q3 | 56.42 Million CNY | -2.58% |
| 2011 Q1 | 80.1 Million CNY | 8.65% |
| 2011 Q4 | 114.9 Million CNY | 103.65% |
| 2011 FY | 114.9 Million CNY | 55.85% |
| 2011 Q2 | 57.92 Million CNY | -27.69% |
| 2010 Q2 | 175.86 Million CNY | 13.71% |
| 2010 Q3 | 110.03 Million CNY | -37.44% |
| 2010 Q4 | 73.72 Million CNY | -32.99% |
| 2010 FY | 73.72 Million CNY | -52.42% |
| 2010 Q1 | 154.66 Million CNY | -0.18% |
| 2009 Q4 | 154.94 Million CNY | 0.0% |
| 2009 FY | 154.94 Million CNY | 81.94% |
| 2008 FY | 85.16 Million CNY | 10.39% |
| 2007 FY | 77.14 Million CNY | 0.0% |